 CohBar, Inc. CWBR, a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that it has resumed the Phase 1b stage of its Phase 1a1b clinical trial of CB4211, its lead candidate for the treatment of nonalcoholic steatohepatitis NASH and obesity. In March 2019, the company announced the temporary pause of the clinical study in response to the COVID-19 pandemic. 